Compare ArcelorMittal SA (MT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Twist Bioscience Corp — how do they compare? ArcelorMittal SA trades at $77.08 (market cap $58.51B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: ArcelorMittal SA is far larger — about 6.9× Twist Bioscience Corp's market cap, and ArcelorMittal SA pays a 0.78% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MT | TWST | |
|---|---|---|
Market Cap | $58.51B | $8.42B |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $153.10 |
52-Week Low | $34.39 | $24.16 |
Enterprise Value | $68.08B | $8.35B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $77.15, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing year-over-year sales growth. Recent news highlights expansion in steel capacity and strategic partnerships, while facing headwinds from weak Chinese demand and geopolitical risks in Ukraine. Cash flow trends show a narrowing net outflow, improving from 2023 levels.
The outlook is cautiously optimistic, supported by analyst consensus and European demand improvements, but risks from industry cyclicality and input cost pressures remain. Investment appeal hinges on execution of growth initiatives and macroeconomic stability in key markets.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
